 Nymox Pharmaceutical Corporation NASDAQ: NYMX has received a Refusal to File RTF letter from FDA regarding its marketing application for Fexapotide Triflutate. Nymoxs position is that clarifications remain to be resolved at a follow-up meeting and that some significant. 